跳到正文
Pharmafile·· 7 天前AI 评分36

ProBioGen柏林病毒生产设施获扩展GMP授权及更新版GMP证书

ProBioGen secures extended GMP authorisation for viral manufacturing facility

AI 导读

ProBioGen柏林病毒生产设施获柏林州卫生与社会事务办公室(Lageso)扩展生产授权及更新版GMP证书,可在原有治疗性蛋白基础上生产病毒载体、疫苗等无菌生物原料药和临床试验用药品。设施原料药产能最高200升,配备内部无菌灌装与质量控制实验室,确认含三项符合EU GMP Annex 1的无菌工艺模拟。该公司还将为Minapharm领导的Bundibugyo埃博拉病毒疫苗项目生产GMP原料药。

正文 · 原文

pharmafile.com | November 16, 2026 | News story | |  GMP, Immunology, Infections and infestations, manufacturing, pharmaceutical 

ProBioGen has secured extended manufacturing authorisation and an updated Good Manufacturing Practice (GMP) certificate for its dedicated viral manufacturing facility in Berlin, allowing it to manufacture sterile biological drug substances and investigational medicinal products, including viral vectors and vaccines.

Granted by the Berlin State Office for Health and Social Affairs (Lageso), the authorisation extends the company’s existing GMP manufacturing services for therapeutic proteins into viral products and advanced therapy medicinal products (ATMPs).

The facility has drug substance production capacity of up to 200 litres, alongside in-house aseptic filling and quality control laboratories. Its integrated capabilities are intended to support customers from process development through GMP manufacturing and filling for clinical supply.

Qualification included three successful aseptic process simulations in accordance with EU GMP Annex 1 requirements for sterile medicinal products. The facility uses restricted access barrier system (RABS) technology for drug product filling and incorporates filter integrity testing into its contamination-control procedures.

ProBioGen will also manufacture GMP drug substance for a Bundibugyo ebolavirus vaccine programme led by Egypt-based Minapharm. The candidate uses ProBioGen’s proprietary MVA-CR19 platform and is being advanced towards clinical evaluation, with Minapharm responsible for commercial drug product manufacturing.

The authorisation also provides a foundation for ProBioGen’s planned role operating a future GMP facility at the Berlin Center for Gene and Cell Therapies, which is currently under construction.

来源:Pharmafile · pharmafile.com